Key result
The CYP2C9*3 allele was associated with a doubled risk of major bleeding among patients taking warfarin for 30 or more days (adjusted OR 2.05; 95% CI 1.04-4.04).
Why the study?
Do CYP2C9, VKORC1, and CYP4F2 genetic variants increase the risk of major bleeding in patients on warfarin therapy?
Population
n=509 patients on warfarin therapy from Vanderbilt's DNA biobank
Comparison
Presence of CYP2C9, VKORC1, and CYP4F2 genetic… vs Absence of the genetic variants
Design
Case-control
Authors
Loading...
Supports closer monitoring in CYP2C9*3 carriers on chronic warfarin; hypothesis-generating pending randomized genotyping trials.
Case-Control (n=509)
No
Do CYP2C9, VKORC1, and CYP4F2 genetic variants increase the risk of major bleeding in patients on warfarin therapy?
Odds Ratio: 2.05 (95% CI 1.04–4.04)
Absolute Event Rate: 14.2% vs 7.8%
p-value: p=0.022
The CYP2C9*3 allele is associated with a doubled risk of major bleeding in patients on warfarin therapy for 30 or more days.
Kawai et al. (2014) conducted a case-control in Major bleeding during warfarin therapy (n=509). CYP2C9*3 allele vs. Absence of CYP2C9*3 allele was evaluated on Major bleeding (OR 2.05, 95% CI 1.04-4.04, p=0.022). The CYP2C9*3 allele was associated with a doubled risk of major bleeding among patients taking warfarin for 30 or more days (adjusted OR 2.05; 95% CI 1.04-4.04).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: